title: Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease.
abstract: We report kinetic modeling results of dynamic acquisition data from 0 to 100 min after injection with the tau PET tracer18F-AV-1451 in 19 subjects.
  
  
  METHODS
  Subjects were clinically diagnosed as 4 young cognitively normal, 5 old cognitively normal, 5 mild cognitive impairment, and 5 Alzheimer disease (AD). Kinetic modeling was performed using Logan graphical analysis with the cerebellum crus as a reference region. Voxelwise binding potential ([Formula: see text]) and SUV ratio ([Formula: see text]) images were compared.
  
  
  RESULTS
  In AD subjects, slower and spatially nonuniform clearance from cortical regions was observed as compared with the controls, which led to focal uptake and elevated retention in the imaging data from 80 to 100 min after injection. BP from the dynamic data from 0 to 100 min correlated strongly (R2> 0.86) with corresponding regional [Formula: see text] values. In the putamen, the observed kinetics (positive [Formula: see text] at the tracer delivery stage and plateauing time-SUVR curves for all diagnostic categories) may suggest either additional off-target binding or a second binding site with different kinetics.
  
  
  CONCLUSIONS
  The kinetics of the18F-AV-1451 tracer in cortical areas, as examined in this small group of subjects, differed by diagnostic stage. A delayed 80- to 100-min scan provided a reasonable substitute for a dynamic 0- to 100-min acquisition for cortical regions although other windows (e.g., 75-105 min) may be useful to evaluate.
authors.affiliation: Eli Lilly & Co, Indianapolis, Indiana shcherbinin_sergey@lilly.com.
authors.forename: Sergey
authors.initials: S
authors.lastname: Shcherbinin
authors.affiliation: Eli Lilly & Co, Indianapolis, Indiana.
authors.forename: Adam J
authors.initials: AJ
authors.lastname: Schwarz
authors.affiliation: Avid Radiopharmaceuticals, Inc., Philadelphia, Pennsylvania.
authors.forename: Abhinay
authors.initials: A
authors.lastname: Joshi
authors.affiliation: Avid Radiopharmaceuticals, Inc., Philadelphia, Pennsylvania.
authors.forename: Michael
authors.initials: M
authors.lastname: Navitsky
authors.affiliation: Avid Radiopharmaceuticals, Inc., Philadelphia, Pennsylvania.
authors.forename: Matthew
authors.initials: M
authors.lastname: Flitter
authors.affiliation: Shankle Clinic and Cognitive Disorders Program, Hoag Neurosciences Institute, Newport Beach, California; and UC Irvine Cognitive Science Department, Irvine, California.
authors.forename: William R
authors.initials: WR
authors.lastname: Shankle
authors.affiliation: Avid Radiopharmaceuticals, Inc., Philadelphia, Pennsylvania.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Devous
authors.affiliation: Avid Radiopharmaceuticals, Inc., Philadelphia, Pennsylvania.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Mintun
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000150:complications / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000503:physiopathology*; D002243:Carbolines; D003071:Cognition; D060825:Cognitive Dysfunction / Q000150:complications*; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D049268:Positron-Emission Tomography; D011849:Radioactive Tracers; D055815:Young Adult; D016875:tau Proteins / Q000378:metabolism*
chemical_list: D002243:Carbolines; D011849:Radioactive Tracers; D016875:tau Proteins; C000591008:7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole
keywords: 18F-AV-1451 (T807); PET; kinetics; neurology; radiotracer tissue; tau; tracer